Michael Riley Dyer

Michael Riley Dyer

Auto-generated profile, based on publicly available information

Michael Riley Dyer

Edward Mallinckrodt Institute of Radiology

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2024 in Nuclear Medicine and Biology
Verified
Journal Article
Closed access
MDMichael R. Dyer
Michael R. Dyer
ZJZhenghan Jing
Zhenghan Jing
KDKathleen Duncan
Kathleen Duncan
JGJacqueline Godbe
Jacqueline Godbe
MSMonica Shokeen
Monica Shokeen

14 January 2026 in Blood Advances
Verified
Journal Article
Open access
MDMichael R. Dyer
Michael R. Dyer
AZAlex Zheleznyak
Alex Zheleznyak
ETErin N. Teubner
Erin N. Teubner
JPJulie L. Prior
Julie L. Prior
BMBrad Manion
Brad Manion
MSMonica Shokeen
Monica Shokeen
Multiple myeloma (MM) is a plasma cell malignancy characterized by bone pain and end-organ failure. A major challenge in treating MM is therapeutic resistance. CD38-targeted immunotherapies, such as daratumumab, have significantly improved outcomes; however, variable responses, resistance, and relapse remain vital challenges. We hypothesized that loss of CD38 drives a more aggressive phenotype and resistance to therapy. To test this, we developed a CD38 knockout (KO) clone of a human MM cell line and evaluated it in immunodeficient mice. Mice with CD38 KO tumors exhibited an increased tumor burden and reduced survival compared with those with CD38 wild-type (WT) tumors. Multimodal imaging and histologic analyses revealed increased osteolytic lesions caused by CD38 KO tumors, while [18F]-fluorodeoxyglucose positron emission tomography demonstrated elevated metabolic activity and tracer uptake. Mice with CD38 KO tumors also developed bilateral renal metastases, whereas none were observed in WT tumors. Blood analysis showed elevated markers of disease progression and renal dysfunction, and cytokine profiling identified increased proinflammatory cytokines within the bone microenvironment. RNA sequencing identified marked transcriptional changes, with enrichment of pathways involving cell adhesion, cytokine signaling, and migration. Daratumumab-resistant MM.1S cells mirrored CD38 KO cells with reduced cell cycle progression and dexamethasone sensitivity, underscoring the microenvironment’s role in driving aggressiveness, and implicating CD38 loss as a possible mediator of cross-resistance. Overall, these findings demonstrate that CD38 loss drives an aggressive MM phenotype characterized by bone degradation, renal metastasis, and reduced survival, highlighting the need to develop strategies to target CD38-deficient clones and identifying RNA signatures as potential regulators of this phenotype.

11 February 2026 in Bioconjugate Chemistry
Verified
Journal Article
Open access
ASAmit Kumar Sharma
Amit Kumar Sharma
RTRui Tang
Rui Tang
AZAlexander Zheleznyak
Alexander Zheleznyak
BMBrad Manion
Brad Manion
ETErin Teubner
Erin Teubner
MSMonica Shokeen
Monica Shokeen
CD38 is an established biomarker of multiple myeloma (MM), and peptide-based radiopharmaceuticals targeted to this receptor offer a route to molecularly specific imaging. In this work, we identified a novel CD38-targeted peptide sequence (HAPWFRGGGGS) through phage display and synthesized it using automated solid-phase peptide synthesis. The peptide was modified by introducing a PEG4 spacer and on-resin conjugation of the DIAMSAR chelator, which forms a stable complex with Copper-64 (Cu-64), yielding DIAMSAR-PEG4-HAPWFRGGGGS (Monomer_L). [64Cu]Cu-Monomer_L was radiolabeled with high molar activity (>98% yield, ∼65 MBq/nmol) but showed suboptimal serum stability (∼45% intact at 2 h). To improve in vivo stability, the l-amino acid sequence was replaced with d-amino acid (Monomer_D), resulting in >90% serum stability and enhanced binding affinity toward CD38, as demonstrated by molecular docking and cell-binding assays in CD38-expressing MOLP2 human MM cells. To further increase avidity, a dimeric analog (Dimer_D) was designed by linking two Monomer_D units via a PEG4 linker. In viable MOLP2 MM cells, tracer uptake ranked as [64Cu]Cu-Dimer_D > [64Cu]Cu-Monomer_D > [64Cu]Cu-Monomer_L, and was markedly reduced by excess unlabeled peptide, confirming CD38-specific binding. Binding specificity and functional engagement of CD38 were further supported by antibody-blocking, enzymatic activity inhibition, and cellular internalization studies. Replacement of L-with d-amino acids improved binding affinity, lowering the Kd from 1043 nM ([64Cu]Cu-Monomer_L) to ∼740 nM ([64Cu]Cu-Monomer_D). The dimerization further lowered the Kd (∼730 nM) with markedly higher Bmax (6993 fmol/mg vs 3024 fmol/mg), consistent with avidity-driven enhancement in receptor engagement. In vivo small animal dynamic PET/CT and ex vivo biodistribution were performed in disseminated and subcutaneous MOLP2-CBR-GFP MM models with naïve controls. Uptake increased with peptide valency, showing maximum femoral uptake of 1.52 ± 0.35 and 2.93 ± 0.68% ID/mL for [64Cu]Cu-Monomer_D and [64Cu]Cu-Dimer_D, respectively, whereas naïve mice exhibited <1% ID/mL over 0-2 h post injection (3-4 MBq; 45-50 pmol). In the subcutaneous model, [64Cu]Cu-Dimer_D enabled clear tumor visualization at 2 h post injection with 4.66 ± 0.20% ID/mL uptake and a T/M ratio of 10.6 ± 3.1. Ex vivo tissue biodistribution confirmed higher femoral uptake (2.26 ± 0.42% ID/g) and femur-to-muscle ratio (18.17 ± 3.26). Autoradiography of excised tissues corroborated tracer localization to tumor-rich regions. Overall, [64Cu]Cu-Dimer_D demonstrates high stability, avidity, and translational promise as a CD38-targeted PET tracer for MM.

21 April 2026 in ACS Applied Bio Materials
Verified
Journal Article
Open access
JGJacqueline M. Godbe
Jacqueline M. Godbe
HZHongwei Zhang
Hongwei Zhang
ASAmit K. Sharma
Amit K. Sharma
KEKatelyn N. Ernst
Katelyn N. Ernst
ZJZhenghan Jing
Zhenghan Jing
MSMonica Shokeen
Monica Shokeen
The lack of targeted molecular imaging agents for multiple myeloma (MM) hinders precise disease characterization and theranostic development. We address this by engineering a tunable platform of self-assembled peptide nanofibers that target CD38, a key antigen in MM. Simple variation of a conjugated lipid tail length (C4-C12) dictates the supramolecular architecture, as revealed by high-resolution cryo-EM. This structural control directly modulates biological function: avidity for CD38 increases monotonically with tail length, culminating in T12 nanofibers with sub-nanomolar affinity. This optimized morphology also enables unique pH-responsive di-tyrosine cross-linking and, critically, facilitates polyvalent cell-surface engagement that outcompetes high-affinity monomers in vitro. The nanofibers are efficiently radiolabeled with 64Cu, exhibit exceptional serum stability, and show no toxicity at doses 20-fold above projected imaging use. By establishing lipid tail length as a simple, powerful handle for controlling nanofiber structure, avidity, and function, we present a robust, translatable platform for advancing targeted imaging and therapy in CD38-positive malignancies.